• 2 FGFR inhibitors received accelerated approval by the FDA for the treatment of patients with previously treated, unresectable locally advanced or metastatic CCA with an FGFR2 fusion or other rearrangement.18,19. This evidence concerns the gene FGFR2 and cholangiocarcinoma.